ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/30/2024
Back to search
Official data from USPTO
MAB2
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
10/30/2024
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
05/25/2021
Registration date
08/15/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/15/2023
Last transaction
08/15/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
11
Owner location
WHITE CITY PLACE, GB
Examiner
KEELEY, ALISON REBECCA
Law office
M40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the lower case letter "M" followed by an upper case letter "A" followed by a lower case letter "B" with a superscript "2" following the "B".
Holders and representatives
Holders
INVOX PHARMA LIMITED
F-STAR THERAPEUTICS LIMITED
F-star Biotechnology Limited
Representatives
Shoko Naruo THOMPSON COBURN LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations containing monoclonal antibodies for scientificindustrialresearch use; bispecific and multispecific monoclonal antibodiesfragments thereoffor scientificindustrialresearch use
Class 5
Pharmaceuticalbiopharmaceutical and medical preparationsagents and substancesall containing or being monoclonal antibodies for medical purposesall for treatment of canceroncological diseases and disordersinfectious diseases and disordersinflammation and diseasesdisorders and conditions associated with inflammationinflammatory diseases and disordersneurological diseases and disorders; bispecific and multispecific monoclonal antibodies for medical use; products in the nature of pharmaceutical preparations and medicines containing multispecificin particular bispecificmonoclonal antibodies for use in medicine; diagnostic preparationsagents and substancesall containing or being monoclonal antibodiesfor medical purposes
Class 42
Scientific and technological servicesnamely scientific research and design in the field of immunoglobulins and antibodies for medical purposes; scientific researchnamely industrial analysis and research servicesin the field of immunoglobulins and antibodies for medical purposes; pharmaceuticalscientific and biopharmaceutical research and development; medical research and development in the field of immunoglobulins and antibodies for medical purposes; drug discovery services; research relating to medicines; research and development of medicines; development of pharmaceutical and biopharmaceutical preparations and medicines; all of the foregoing involving monoclonal antibodies
Publications
History of USPTO decisions and trademark events.
28 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/15/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/15/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/30/2023
PUBO
PUBLISHED FOR OPPOSITION
05/30/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/27/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
04/27/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/27/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/27/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/27/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/20/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/20/2022
GNRT
NON-FINAL ACTION E-MAILED
09/20/2022
CNRT
NON-FINAL ACTION WRITTEN
09/20/2022
DOCK
ASSIGNED TO EXAMINER
08/16/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/28/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/28/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/28/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/19/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/08/2022
GNRT
NON-FINAL ACTION E-MAILED
02/08/2022
CNRT
NON-FINAL ACTION WRITTEN
02/08/2022
DOCK
ASSIGNED TO EXAMINER
02/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/20/2021
NWAP
NEW APPLICATION ENTERED
05/28/2021
Continuous trademark protection
Get notified about every new filing that threatens MAB2 or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.